ATE162219T1 - Transformation von tierischen hautzellen mit hilfe von partikeln - Google Patents

Transformation von tierischen hautzellen mit hilfe von partikeln

Info

Publication number
ATE162219T1
ATE162219T1 AT91901057T AT91901057T ATE162219T1 AT E162219 T1 ATE162219 T1 AT E162219T1 AT 91901057 T AT91901057 T AT 91901057T AT 91901057 T AT91901057 T AT 91901057T AT E162219 T1 ATE162219 T1 AT E162219T1
Authority
AT
Austria
Prior art keywords
cells
microprojectiles
transformation
particles
target cells
Prior art date
Application number
AT91901057T
Other languages
English (en)
Inventor
Stephen A Johnston
R Sanders Williams
John C Sanford
Sandra G Mcelligott
Original Assignee
Univ Duke
Cornell Res Foundation Inc
Du Pont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke, Cornell Res Foundation Inc, Du Pont filed Critical Univ Duke
Application granted granted Critical
Publication of ATE162219T1 publication Critical patent/ATE162219T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M35/00—Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
    • C12M35/04—Mechanical means, e.g. sonic waves, stretching forces, pressure or shear stimuli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • C12N15/895—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection using biolistic methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mechanical Engineering (AREA)
  • Cell Biology (AREA)
  • Sustainable Development (AREA)
  • Dermatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT91901057T 1989-11-16 1990-11-13 Transformation von tierischen hautzellen mit hilfe von partikeln ATE162219T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43784889A 1989-11-16 1989-11-16

Publications (1)

Publication Number Publication Date
ATE162219T1 true ATE162219T1 (de) 1998-01-15

Family

ID=23738164

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91901057T ATE162219T1 (de) 1989-11-16 1990-11-13 Transformation von tierischen hautzellen mit hilfe von partikeln

Country Status (11)

Country Link
US (6) US6194389B1 (de)
EP (1) EP0500799B1 (de)
JP (2) JPH05503841A (de)
AT (1) ATE162219T1 (de)
AU (1) AU6964191A (de)
CA (1) CA2068863C (de)
DE (1) DE69031951T2 (de)
DK (1) DK0500799T3 (de)
ES (1) ES2113371T3 (de)
GR (1) GR3026594T3 (de)
WO (1) WO1991007487A1 (de)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6867195B1 (en) 1989-03-21 2005-03-15 Vical Incorporated Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US6214804B1 (en) 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
ATE162219T1 (de) * 1989-11-16 1998-01-15 Univ Duke Transformation von tierischen hautzellen mit hilfe von partikeln
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US6706694B1 (en) 1990-03-21 2004-03-16 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
CA2102918C (en) * 1992-03-11 2007-05-08 Joel R. Haynes Genetic vaccine for immunodeficiency viruses
WO1993024626A1 (en) * 1992-05-28 1993-12-09 Scientific Dimensions Usa, Inc. Transgenic animal production with biolistically transformed spermatozoa
GB2282139A (en) * 1993-09-24 1995-03-29 Univ Reading Introducing DNA into the germ line of birds
US6995008B1 (en) 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
DE4416784A1 (de) * 1994-05-09 1995-11-30 Soft Gene Gmbh Methode zur Anreicherung von Zellen, die durch ballistischen Transfer modifiziert wurden
US7223739B1 (en) 1995-06-07 2007-05-29 Powderject Vaccines, Inc. Adjuvanted genetic vaccines
WO1997039722A2 (en) * 1996-04-25 1997-10-30 T Cell Sciences, Inc. Method of isolating regulators of t cell activation
US6893664B1 (en) * 1996-06-17 2005-05-17 Powderject Research Limited Particle delivery techniques
WO1998004720A1 (en) * 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
US6433154B1 (en) * 1997-06-12 2002-08-13 Bristol-Myers Squibb Company Functional receptor/kinase chimera in yeast cells
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
IL142680A0 (en) * 1998-10-19 2002-03-10 Powderject Vaccines Inc Minimal promoters and uses thereof
US6881723B1 (en) 1998-11-05 2005-04-19 Powderject Vaccines, Inc. Nucleic acid constructs
IL144597A0 (en) 1999-02-03 2002-05-23 Powderject Res Ltd Hydrogel particle formulations
WO2000047227A2 (en) 1999-02-09 2000-08-17 Powderject Vaccines, Inc. Mycobacterium tuberculosis, immunization
US7196066B1 (en) 1999-11-03 2007-03-27 Powderject Vaccines, Inc. DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
US20040234539A1 (en) * 1999-11-03 2004-11-25 Powderject Research Limited Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression
US20040109874A1 (en) * 1999-11-10 2004-06-10 Powderject Vaccines, Inc. Induction of mucosal immunity by vaccination via the skin route
CN1254541C (zh) 2000-02-23 2006-05-03 史密丝克莱恩比彻姆生物有限公司 新化合物
GB0008494D0 (en) * 2000-04-07 2000-05-24 Secr Defence Microprojectile delivery system
US6764720B2 (en) 2000-05-16 2004-07-20 Regents Of The University Of Minnesota High mass throughput particle generation using multiple nozzle spraying
EP1319069B1 (de) 2000-06-28 2008-05-21 Corixa Corporation Zusammensetzungen und verfahren für therapie und diagnose von lungenkrebs
US20020086036A1 (en) 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
US7255865B2 (en) 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
CA2446788A1 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7247338B2 (en) 2001-05-16 2007-07-24 Regents Of The University Of Minnesota Coating medical devices
US7414032B2 (en) * 2001-06-25 2008-08-19 Immunofrontier, Inc. Vaccine comprising a polynucleotide encoding an antigen recognized by a CD4+ helper T-cell and a polynucleotide encoding a tumor specific or associated antigen recognized by a CD8+ CTL
MXPA04002631A (es) 2001-09-20 2004-07-08 Glaxo Group Ltd Vacunas de adn optimizadas por codon gag-vih.
EP1581119B1 (de) 2001-12-17 2013-01-30 Corixa Corporation Zusammensetzungen und verfahren zur behandlung und diagnose von entzündlicher darmerkrankung
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
DK1589934T3 (en) 2003-01-06 2015-12-21 Corixa Corp Certain AMINOAL COOLER GLUCOSAMINIDE PHOSPHATE COMPOUNDS AND APPLICATION
US7892205B2 (en) * 2003-06-06 2011-02-22 Boston Scientific Scimed, Inc. Device and method for delivering micronized therapeutic agents in the body
US7663017B2 (en) 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
WO2005070122A2 (en) * 2004-01-09 2005-08-04 Boards Of Regents, The University Of Texas System Mechanosensitive ion channels and methods of use
TW200604526A (en) * 2004-06-18 2006-02-01 Unviersity Of Minnesota Identifying virally infected and vaccinated organisms
EP2298340B1 (de) 2004-09-22 2014-04-16 GlaxoSmithKline Biologicals S.A. Immunogene Zusammensetzung zur Verwendung zur Impfung gegen Staphylokokken
US7449200B2 (en) * 2006-04-17 2008-11-11 Gp Medical, Inc. Nanoparticles for protein/peptide delivery and delivery means
US8137697B1 (en) 2004-10-05 2012-03-20 Gp Medical, Inc. Nanoparticles for protein/peptide delivery and delivery means thereof
US7901711B1 (en) 2006-04-17 2011-03-08 Gp Medical, Inc. Nanoparticles for protein/peptide delivery and delivery means thereof
EP1838853A2 (de) * 2005-01-06 2007-10-03 Benitec, Inc. Rnai-mittel zur pflege von stammzellen
US8841259B2 (en) * 2005-02-24 2014-09-23 Joslin Diabetes Center Compositions and methods for treating vascular permeability
PT2369001T (pt) 2005-06-24 2016-10-25 Univ Minnesota Vírus srrp, clones infecciosos, os seus mutantes e processos de utilização
US20090081157A1 (en) 2006-01-09 2009-03-26 Richard Syd Kornbluth Immunostimulatory Combinations for Vaccine Adjuvants
US7951428B2 (en) 2006-01-31 2011-05-31 Regents Of The University Of Minnesota Electrospray coating of objects
EP2529761B1 (de) 2006-01-31 2017-06-14 Nanocopoeia, Inc. Oberflächenbeschichtung mit nanoteilchen
US9108217B2 (en) 2006-01-31 2015-08-18 Nanocopoeia, Inc. Nanoparticle coating of surfaces
US8449915B1 (en) 2006-04-17 2013-05-28 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
WO2007136758A2 (en) * 2006-05-19 2007-11-29 Board Of Regents, The University Of Texas System Sirna inhibition of p13k p85, p110, and akt2 and methods of use
US9040816B2 (en) 2006-12-08 2015-05-26 Nanocopoeia, Inc. Methods and apparatus for forming photovoltaic cells using electrospray
US8454954B2 (en) 2007-05-16 2013-06-04 The Brigham And Women's Hospital, Inc. Treatment of synucleinopathies
US9593340B2 (en) 2007-10-15 2017-03-14 Admedus Vaccines Pty Ltd. Expression system for modulating an immune response
US9207242B2 (en) 2008-10-09 2015-12-08 The University Of Hong Kong Cadherin-17 as diagnostic marker and therapeutic target for liver cancer
WO2010105096A2 (en) 2009-03-11 2010-09-16 University Of Massachusetts Modulation of human cytomegalovirus replication by micro-rna 132 (mir132), micro-rna 145 (mir145) and micro-rna 212 (mir212)
EP2756845B1 (de) 2009-04-03 2017-03-15 Dicerna Pharmaceuticals, Inc. Verfahren und Zusammensetzungen für spezifische KRAS-Hemmung mit asymmetrischer Doppelstrang-RNA
EP2482837A4 (de) 2009-09-29 2013-05-22 Joslin Diabetes Center Inc Verwendung von proteinkinase-c-delta (pkcd-)hemmern zur behandlung von diabetes, adipositas und leberverfettung
MD4087C1 (ro) * 2010-02-10 2011-08-31 Государственный Университет Молд0 Procedeu chimico-catalitic de depunere a acoperirilor metalice
US8841269B2 (en) * 2010-02-23 2014-09-23 Creighton University Polynucleotides for use in treating and diagnosing cancers
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
CN103608030A (zh) 2011-06-21 2014-02-26 昂科发克特公司 用于治疗和诊断癌症的组合物和方法
US20150240238A1 (en) 2011-11-17 2015-08-27 The Regents Of The University Of California Therapeutic rna switches compositions and methods of use
EP2846825B1 (de) 2012-03-14 2021-05-05 The Regents of The University of California Behandlung von entzündlichen erkrankungen bei nichtmenschlichen säugern
US20160002316A1 (en) 2013-02-22 2016-01-07 Joslin Diabetes Center Serpins: methods of therapeutic beta-cell regeneration and function
EP2851086A1 (de) 2013-09-20 2015-03-25 Sanofi Serpine: Verfahren zur therapeutischen ß-Zellen-Regeneration und Funktion
EP2769732A1 (de) 2013-02-22 2014-08-27 Sanofi Serpine: Verfahren zur therapeutischen Beta-Zellen-Regeneration und Funktion
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
US10420826B2 (en) 2014-11-11 2019-09-24 Massachusetts Eye & Ear Infirmary Conjunctivitis vaccines
ES2747842T3 (es) 2014-12-15 2020-03-11 Dicerna Pharmaceuticals Inc Acidos nucleicos de doble hebra modificados por ligando
JP2018511655A (ja) 2015-03-20 2018-04-26 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ボルデテラ属に対するワクチン接種における使用のための免疫原性組成物
EP3277815B1 (de) 2015-04-03 2021-09-22 University of Massachusetts Oligonukleotidverbindungen zur behandlung von präeklampsie und anderen angiogenen erkrankungen
JP7009356B2 (ja) 2015-04-03 2022-01-25 ユニバーシティ・オブ・マサチューセッツ ハンチンチンｍＲＮＡをターゲティングするオリゴヌクレオチド化合物
WO2016161388A1 (en) 2015-04-03 2016-10-06 University Of Massachusetts Fully stabilized asymmetric sirna
WO2016179497A1 (en) 2015-05-07 2016-11-10 Shire Human Genetic Therapies, Inc. Glucocerebrosidase gene therapy for parkinson's disease
WO2017027810A2 (en) 2015-08-12 2017-02-16 The General Hospital Corporation Compositions and methods that promote hypoxia or the hypoxia response for treatment and prevention of mitochondrial dysfunction and oxidative stress disorders
WO2017030973A1 (en) 2015-08-14 2017-02-23 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
JP7628764B2 (ja) 2015-09-29 2025-02-12 アムジエン・インコーポレーテツド Ａｓｇｒ阻害剤
CA3005878A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
CA3006779A1 (en) 2015-12-09 2017-06-15 Admedus Vaccines Pty Ltd Immunomodulating composition for treatment
US10478503B2 (en) 2016-01-31 2019-11-19 University Of Massachusetts Branched oligonucleotides
WO2018018082A1 (en) 2016-07-26 2018-02-01 The Australian National University Immunostimulatory compositions and uses therefor
US11753638B2 (en) 2016-08-12 2023-09-12 University Of Massachusetts Conjugated oligonucleotides
US10443055B2 (en) 2016-12-22 2019-10-15 Beth Israel Deaconess Medical Center Compounds that target MYC microRNA responsive elements for the treatment of MYC-associated cancer
CA3064590A1 (en) 2017-06-23 2018-12-27 University Of Massachusetts Two-tailed self-delivering sirna and related methods
EP3664834A1 (de) 2017-08-11 2020-06-17 Dana Farber Cancer Institute, Inc. Verwendung eines botulinumtoxinmittels zur behandlung von plasmazellstörungen
EP3668309A4 (de) 2017-08-14 2021-06-09 University of Georgia Research Foundation, Inc. Proteine mit pneumokokken-kapsel-abbauender aktivität und verwendungsverfahren
WO2019036375A1 (en) 2017-08-14 2019-02-21 Sanford Burnham Prebys Medical Discovery Institute CARDIOGENIC MESODERMA TRAINING REGULATORS
WO2019089216A1 (en) 2017-11-01 2019-05-09 Dana-Farber Cancer Institute, Inc. Methods of treating cancers
SG11202010841QA (en) 2018-05-11 2020-11-27 Alpha Anomeric Sas Oligonucleotides conjugates comprising 7'-5'-alpha-anomeric-bicyclic sugar nucleosides
WO2020033899A1 (en) 2018-08-10 2020-02-13 University Of Massachusetts Modified oligonucleotides targeting snps
JP7627042B2 (ja) 2018-08-23 2025-02-05 ユニバーシティー オブ マサチューセッツ Ｏ－メチルリッチ完全安定化オリゴヌクレオチド
US12281308B2 (en) 2018-08-29 2025-04-22 University Of Massachusetts Inhibition of protein kinases to treat Friedreich ataxia
US11793834B2 (en) 2018-12-12 2023-10-24 Kite Pharma, Inc. Chimeric antigen and T cell receptors and methods of use
WO2020146758A1 (en) 2019-01-10 2020-07-16 The General Hospital Corporation Methods to treat mitochondrial-associated dysfunctions or diseases
WO2020150636A1 (en) 2019-01-18 2020-07-23 University Of Massachusetts Dynamic pharmacokinetic-modifying anchors
WO2020227395A2 (en) 2019-05-06 2020-11-12 University Of Massachusetts Anti-c9orf72 oligonucleotides and related methods
CA3149835A1 (en) 2019-08-09 2021-02-18 University Of Massachusetts Chemically modified oligonucleotides targeting snps
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
EP4081302A4 (de) 2019-12-23 2025-01-29 University Of Massachusetts Oligonukleotide zur gewebespezifischen genexpressionsmodulation
US12312585B2 (en) 2020-02-14 2025-05-27 University Of Massachusetts Oligonucleotides targeting frataxin and related methods
JP2023516028A (ja) 2020-02-28 2023-04-17 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 多重特異性抗体を介したトランスフォーミング増殖因子ベータスーパーファミリーシグナル伝達の選択的調節
US12258566B2 (en) 2020-02-28 2025-03-25 University Of Massachusetts Oligonucleotides for PRNP modulation
WO2021195089A1 (en) 2020-03-23 2021-09-30 Sorrento Therapeutics, Inc. Fc-coronavirus antigen fusion proteins, and nucleic acids, vectors, compositions and methods of use thereof
US12146136B2 (en) 2020-03-26 2024-11-19 University Of Massachusetts Synthesis of modified oligonucleotides with increased stability
WO2021195510A1 (en) 2020-03-27 2021-09-30 University Of Massachusetts Dual-acting sirna based modulation of c9orf72
AU2021261241A1 (en) 2020-04-23 2022-11-24 The Schepens Eye Research Institute, Inc. Methods and materials for treatment of fibrosis
EP4157289A4 (de) 2020-05-26 2024-06-26 University Of Massachusetts Synthetische oligonukleotide mit block- und cluster-modifikationsregionen
WO2022016035A1 (en) 2020-07-17 2022-01-20 University Of Georgia Research Foundation, Inc. Β-glucuronidase proteins having pneumococcal capsule degrading activity and methods of use
AR126207A1 (es) 2021-06-23 2023-09-27 Univ Massachusetts Compuestos de oligonucleotidos anti-flt1 optimizados para el tratamiento de la preeclampsia y otros desordenes angiogénicos

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7781E (fr) 1907-04-16 1907-10-11 Jacques Delpech Procédé ayant pour but de supprimer le tremblement apparent des projections cinématographiques
US3931397A (en) * 1971-11-05 1976-01-06 Beecham Group Limited Biologically active material
GB1594097A (en) * 1976-12-16 1981-07-30 Int Inst Of Differentiation Production of specific immune nucleic acids cell dialysates and antibodies
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
EP0091539B2 (de) * 1982-03-31 1996-11-27 Ajinomoto Co., Inc. Das Polypeptid Interleukin-2 kodierendes Gen, rekombinante, dieses Gen enthaltende DNA, diese rekombinante DNA aufweisende Zelllinien und Verfahren zur Herstellung von Interleukin-2 unter Verwendung der genannten Zellen
US4798786A (en) 1982-05-06 1989-01-17 Stolle Research And Development Corporation Living cells encapsulated in crosslinked protein
US4870009A (en) * 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
NZ209840A (en) * 1983-10-17 1988-11-29 Kaji Akira A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action
US4761375A (en) * 1984-05-08 1988-08-02 Genetics Institute, Inc. Human interleukin-2 cDNA sequence
WO1986000930A1 (en) 1984-07-20 1986-02-13 Worcester Foundation For Experimental Biology Retroviral vaccines and vectors and methods for their construction
US4699880A (en) * 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US5100792A (en) 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US4704692A (en) * 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5015580A (en) 1987-07-29 1991-05-14 Agracetus Particle-mediated transformation of soybean plants and lines
IL84459A (en) 1986-12-05 1993-07-08 Agracetus Apparatus and method for the injection of carrier particles carrying genetic material into living cells
US4944942A (en) 1987-08-27 1990-07-31 Mobay Corporation Intranasal vaccination of horses with inactivated microorganisms or antigenic material
US4945000A (en) * 1989-01-18 1990-07-31 Btl Specialty Resins Corp. Particulate thermosetting adhesive compositions
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0737750B1 (de) 1989-03-21 2003-05-14 Vical, Inc. Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
DK0431135T3 (da) * 1989-06-26 2003-07-21 Powderject Vaccines Inc Partikelmedieret transformation af somatiske dyreceller
ATE162219T1 (de) 1989-11-16 1998-01-15 Univ Duke Transformation von tierischen hautzellen mit hilfe von partikeln
US5204253A (en) * 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
JPH09501936A (ja) * 1993-08-26 1997-02-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 生物活性ペプチドをコードする裸のポリヌクレオチドを投与するための方法、組成物および装置
US5703057A (en) * 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
CA2237316C (en) 1995-11-30 2012-06-26 Vical Incorporated Complex cationic lipids
US5994317A (en) 1996-04-09 1999-11-30 Vical Incorporated Quaternary cytofectins

Also Published As

Publication number Publication date
US6194389B1 (en) 2001-02-27
DK0500799T3 (da) 1998-09-14
EP0500799A1 (de) 1992-09-02
CA2068863A1 (en) 1991-05-17
CA2068863C (en) 2009-06-02
US20040097458A1 (en) 2004-05-20
US20080138325A1 (en) 2008-06-12
ES2113371T3 (es) 1998-05-01
EP0500799B1 (de) 1998-01-14
US20040170616A1 (en) 2004-09-02
US20020006637A1 (en) 2002-01-17
EP0500799A4 (en) 1993-05-05
US20040092019A1 (en) 2004-05-13
WO1991007487A1 (en) 1991-05-30
DE69031951T2 (de) 1998-08-13
JP2001103968A (ja) 2001-04-17
US7449449B2 (en) 2008-11-11
DE69031951D1 (de) 1998-02-19
AU6964191A (en) 1991-06-13
GR3026594T3 (en) 1998-07-31
JPH05503841A (ja) 1993-06-24
US7358234B2 (en) 2008-04-15

Similar Documents

Publication Publication Date Title
DE69031951D1 (de) Transformation von tierischen Hautzellen mit hilfe von Partikeln
EP1225225A3 (de) Osteogene Vorrichtungen
LU90855I2 (en) Proteine 1 osteogenique recombinante humaine: bmp-7 et ses d-riv-s pharmaceutiquement acceptables
KR890005150A (ko) 혈청 담체 단백질에 대한 결합력이 저하된 사람의 인슐린-유사 성장 인자 동족체, 및 효모내에서의 이의 생산방법
DE1213032T1 (de) Behandlung von Krankheiten durch ortsspezifische Instillation von Zellen oder ortsspezifischer Transformation von Zellen sowie Ausrüstung dafür
DE69632536D1 (de) Impfstoffe für das respiratorische-synzytial-virus mit nuklein säuren
ATE99330T1 (de) Rekombinantes viren-ueberzugsprotein assoziiert mit ''acquired immune deficiency syndrome'' (aids) und verfahren zur testung von aids.
DK592186A (da) Fremgangsmaade til udvinding af proteiner
DK288183A (da) Fremgangsmaade til fremstilling af et oligonucleotidt terapeutisk middel
MA20411A1 (fr) Procede de preparation de polypeptides ayant l'activite du gamma-interferon humain
EP0216742A3 (de) Wachstumsfaktoren
CA2290696A1 (en) Immunopotentiating composition
DK336986A (da) Fremgangsmaade til fremstilling af taerre biologisk aktive rekombinante vaeksthormoner
DE3864500D1 (de) Verfahren und anlage zum konditionieren von mit lebenden zellen beschichteten kunststofftraegern.
DE69822164D1 (de) Verfahren zur identifizierung von verbindungen mit verminderter systemischer aktivität
BG49827A3 (bg) Метод за получаване на пречистен биологично активен рекомбинантен човешки колоний стимулиращ фактор
KR900002795A (ko) 하이브리드 단백질c 작제물 및 그들의 제조방법
DK610888D0 (da) Cardiodilatinfragmentet, fremgangsmaade til fremstilling deraf samt dets anvendelse
EP0228192A3 (de) Renin-hemmende Oligopeptide, deren Herstellung und Anwendung
DE69633393D1 (de) Mitteln zur behandlung von auto-immun krankheiten
EP0397560A3 (de) Spheroidin-DNS und rekombinante Expressionsvektoren von Entomopoxviren
Vane et al. Genetic engineering and pharmaceuticals
KR890008317A (ko) 유전학적 조작에 의한 응고억제성 단백질 pp4의 제조방법
KR900005994A (ko) 혈소판 감소증 또는 혈소판 기능장애로 인한 질병 치료용 약학적 제제
EP0315118A3 (de) Endothelin kodierendes DNA und dessen Verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time